Lung Cancer
News
Company for Crizotinib? New ALK Inhibitors Attack Lung Cancer
Major Finding: Response rates reached as high as 85% in patients with advanced tumors that were predominantly non-small cell lung cancer.Data...
News
FDA Approves Abraxane for Non-Small Cell Lung Cancer
News
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)
News
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
News
Crizotinib Changes Practice for Advanced ALK-Positive NSCLC
Major Finding: Median progression-free survival was 3.0 months with chemotherapy and 7.7 months with crizotinib (P less than .0001; hazard ratio 0...
News
Experimental Pemetrexed Regimen No Boon to Lung Cancer Survival
Major Finding: Median overall survival – the primary end point – was 12.6 months for the pemetrexed regimen and 13.4 months for the paclitaxel...
News
Prophylactic Cranial Irradiation Fails to Improve NSCLC Survival
Major Finding: There were no significant differences between prophylactic cranial irradiation and observation in the 5-year rates of survival (26....
News
Early Lung Cancer Patients Living Longer After Radiotherapy
Major Finding: When stage I NSCLC was treated with radiation alone, median survival improved significantly, from 16 months during 1999-2003 to 21...